Novo Nordisk
Global healthcare company with 95 years of innovation and leadership in diabetes care.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | Post IPO Equity | |
| Total Funding | 000k | ||
| DKK | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 11 % | 26 % | 31 % | 25 % | 14 % | 15 % | 11 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 48 % | 46 % | 49 % | 48 % | 50 % | 51 % | 51 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 34 % | 31 % | 36 % | 35 % | 35 % | 36 % | 37 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 13 % | 14 % | 14 % | 17 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Novo Nordisk, founded in 1923 and headquartered in Denmark, is a leading global healthcare company specializing in diabetes care, obesity treatment, and chronic disease management. The company develops and manufactures innovative medicines that are approved for specific indications in various countries and regions. Novo Nordisk serves a diverse range of clients, including healthcare providers, patients, and governments, operating primarily in the pharmaceutical and biotechnology markets. The business model focuses on research and development, production, and distribution of life-saving medicines, generating revenue through the sale of these pharmaceutical products. The company is committed to sustainability, aiming to reduce its environmental impact while expanding access to essential medicines for vulnerable populations. Novo Nordisk is also dedicated to building strong relationships with suppliers and continuously seeks talented individuals to join their team.
Keywords: diabetes care, obesity treatment, chronic disease, innovative medicines, healthcare, biotechnology, sustainability, pharmaceutical, research and development, global market.
Tech stack
